Table A.
Multivariate Logistic Regression Analyses – Patients with HIV-1 RNA > 400 (n=15157/11707)
| Established Care | Met Retention Criterion in All Outpatient Years | No Loss to Follow-up > 12 months | Met all Three Criteria | |
|---|---|---|---|---|
| Gender | ||||
| Female | ---- | ---- | ---- | ---- |
| Male | 0.82 (0.69, 0.96)** | 0.84 (0.73, 0.97)* | 0.90 (0.77 1.05) | 0.80 (0.70, 0.91)** |
| Race/Ethnicity | ||||
| White | ---- | ---- | ---- | ---- |
| Black | 1.15 (1.08, 1.22)*** | 0.88 (0.81, 0.96)** | 1.36 (1.13, 1.63)*** | 1.08 (0.95, 1.23) |
| Hispanic | 1.27 (1.03, 1.57)* | 1.01 (0.95, 1.08) | 1.48 (1.19, 1.85)** | 1.27 (1.06, 1.53)* |
| Other | 1.01 (0.82, 1.25) | 1.04 (0.81, 1.33) | 1.33 (0.97, 1.82) | 1.19 (0.88, 1.61) |
| Missing | 0.47 (0.33, 0.68)*** | 0.84 (0.61, 1.15) | 0.88 (0.42, 1.88) | 0.61 (0.36, 1.06) |
| Risk Group | ||||
| MSM | ---- | ---- | ---- | ---- |
| HET | 0.88 (0.79, 0.98)** | 0.84 (0.73, 0.97)* | 1.05 (0.95, 1.17) | 0.86 (0.78, 0.95)** |
| IDU | 0.46 (0.38, 0.57)*** | 0.90 (0.72, 1.13) | 0.68 (0.57, 0.82)*** | 0.58 (0.50, 0.68)*** |
| HET+IDU | 0.90 (0.68, 1.19) | 0.93 (0.73, 1.17) | 0.96 (0.75, 1.23) | 0.87 (0.63, 1.20) |
| MSM+IDU | 1.09 (0.80, 1.48) | 1.00 (0.86, 1.16) | 1.00 (0.65, 1.54) | 1.01 (0.67, 1.53) |
| Missing | 0.26 (0.15, 0.46)*** | 1.19 (0.92, 1.56) | 0.45 (0.24, 0.88)* | 0.40 (0.21, 0.78)** |
| Age at Enrollment | ||||
| 18-29 | ---- | ---- | ---- | ---- |
| 30-39 | 1.03 (0.93, 1.14) | 1.15 (1.05, 1.26)** | 1.07 (0.94, 1.22) | 1.14 (1.04, 1.25)*** |
| 40-49 | 1.23 (1.01, 1.49)* | 1.29 (1.16, 1.43)*** | 1.23 (1.11, 1.37)*** | 1.45 (1.33, 1.58)*** |
| 50+ | 1.34 (1.14, 1.57)*** | 1.61 (1.39, 1.87)*** | 1.52 (1.26, 1.84)*** | 1.94 (1.70, 2.20)*** |
| Initial Insurance | ||||
| Private | ---- | ---- | ---- | ---- |
| Medicaid | 0.83 (0.70, 0.99)* | 1.04 (0.90, 1.21) | 0.86 (0.70, 1.04) | 0.89 (0.70, 1.12) |
| Medicare/Dual | 0.65 (0.51, 0.82)* | 1.29 (0.99, 1.67) | 0.85 (0.62, 1.17) | 1.00 (0.72, 1.38) |
| None/Ryan White | 0.76 (0.57, 0.99)* | 1.02 (0.93, 1.12) | 0.88 (0.74, 1.04) | 0.89 (0.75, 1.05) |
| Missing | 0.74 (0.60, 0.91)** | 0.96 (0.79, 1.16) | 0.90 (0.71, 1.13) | 0.89 (0.75, 1.05) |
| Initial CD4 Cell Count | ||||
| <50 | ---- | ---- | ---- | ---- |
| 51-200 | 1.07 (0.88, 1.30) | 0.84 (0.78, 0.91)*** | 0.79 (0.68, 0.93)** | 0.77 (0.70, 0.85)*** |
| 201-350 | 0.91 (0.75, 1.10) | 0.84 (0.74, 0.94)** | 0.76 (0.61, 0.96)* | 0.71 (0.59, 0.86)*** |
| 351-500 | 0.96 (0.78, 1.17) | 0.74 (0.65, 0.84)*** | 0.74 (0.61, 0.90)** | 0.65 (0.57, 0.74)*** |
| 501+ | 0.94 (0.77, 1.15) | 0.72 (0.64, 0.81)*** | 0.67 (0.53, 0.85)*** | 0.59 (0.52, 0.68)*** |
| Missing | 4.16 (1.35,12.83)*** | 0.55 (0.32, 0.94)* | 0.79 (0.53, 1.17) | 0.98 (0.56, 1.70) |
| Year of First Visit | ||||
| 2001 | ---- | ---- | ---- | ---- |
| 2002 | 1.28 (0.90, 1.81) | 1.08 (0.97, 1.20) | 1.13 (0.95, 1.33) | 1.35 (1.02, 1.80)** |
| 2003 | 1.22 (0.83, 1.80) | 1.22 (1.00, 1.49)* | 1.26 (1.07, 1.48)** | 1.65 (1.25, 2.17)*** |
| 2004 | 1.01 (0.72, 1.41) | 1.33 (1.16, 1.53)*** | 1.37 (1.14, 1.66)*** | 1.64 (1.22, 2.20)*** |
| 2005 | 0.84 (0.54, 1.29) | 1.48 (1.31, 1.67)*** | 1.73 (1.35, 2.23)*** | 2.01 (1.53, 2.64)*** |
| 2006 | 0.96 (0.64, 1.45) | 1.70 (1.38, 2.08)*** | 2.40 (1.93, 2.98)*** | 2.85 (2.30, 3.53)*** |
| 2007 | 0.88 (0.65, 1.20) | 1.95 (1.58, 2.42)*** | 4.08 (3.18, 5.25)*** | 3.50 (2.62, 4.68)*** |
| 2008 | 0.73 (0.55, 0.99)* | 3.15 (2.62, 3.78)*** | 22.14 (16.13, 30.37)** | 6.63 (4.84, 9.08)*** |
Note: Entries are adjusted odds-ratios (95% CIs). MSM – Men who have sex with men; IDU – injection drug use; HET – heterosexual transmission. All models included indicators for treatment site.
*
p<0.05
**
p<0.01
***
p< 0.001